CompanyGraph
Beijing Bohui Innovation Technology Co., Ltd.
300318 · SZSE · China
bohui-tech.comFinancials as of FY2025
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- PositionCurrent ratio is 0.94×, lower than 95% of its Biotechnology peers (median 5.64×)
- FinancialsAltman Z-Score 1.1: grey zone
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
4.05BCNY601.78M · vs all stocks (USD)
Revenue (TTM)
812.78MCNY120.71M · vs all stocks (USD)
Profit Margin
-11.71%vs Biotechnology peers
Beta
0.0870xvs all stocks
52-Week Change
-23.10%vs all stocks
Market Capitalization
4.05BCNY601.78M · vs all stocks (USD)
Enterprise Value
5.82BCNY863.75M · vs all stocks (USD)
Price to Sales (TTM)
5.06xvs Biotechnology peers
Price to Book (MRQ)
3.21xvs Biotechnology peers
Enterprise to Revenue
7.16xvs Biotechnology peers
Enterprise to EBITDA
130.63xvs Biotechnology peers
Gross Margin
29.72%vs Biotechnology peers
Profit Margin
-11.71%vs Biotechnology peers
Operating Margin
1.28%vs Biotechnology peers
Return on Assets (TTM)
-0.60%vs Biotechnology peers
Return on Equity (TTM)
-8.00%vs Biotechnology peers
Revenue (TTM)
812.78MCNY120.71M · vs all stocks (USD)
Revenue per Share (TTM)
0.9920CNYUpdated Aug 19, 2026Quarterly Revenue Growth
-5.80%vs Biotechnology peers
Gross Profit (TTM)
273.74MCNY40.66M · vs all stocks (USD)
EBITDA (TTM)
51.19MCNY7.60M · vs all stocks (USD)
Net Income (TTM)
-95.15MCNY-14.13M · vs all stocks (USD)
Operating Cash Flow (TTM)
-143.87MCNY-21.37M · vs all stocks (USD)
Payout Ratio
0.00%vs Biotechnology peers
Minority Interest (Equity)
890.81MCNYFY2025 · Dec 31, 2025Revenue
824.58MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
498.40MCNYFY2025 · Dec 31, 2025Gross Profit
326.17MCNYFY2025 · Dec 31, 2025Operating Income
6.95MCNY1.03M · vs all stocks (USD)
Pre-tax Income
-171.31MCNYFY2025 · Dec 31, 2025Income Tax Expense
694.86KCNYFY2025 · Dec 31, 2025Net Income
-172.01MCNYFY2025 · Dec 31, 2025EBIT
-137.89MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
51.19MCNYFY2025 · Dec 31, 2025Research & Development
64.92MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
82.62MCNYFY2025 · Dec 31, 2025Other Operating Expenses
15.63MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
1.98MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
33.43MCNYFY2025 · Dec 31, 2025EPS (Basic)
-0.1125CNYFY2025 · Dec 31, 2025EPS (Diluted)
-0.1125CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
817.10MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
817.10MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-172.01MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
80.08MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
-347.79MCNYFY2025 · Dec 31, 2025Free Cash Flow
-474.42MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
103.33MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-172.01MCNYFY2025 · Dec 31, 2025Other Non-cash Items
46.41MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-52.78MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-169.41MCNYFY2025 · Dec 31, 2025Capital Expenditures
-126.63MCNYFY2025 · Dec 31, 2025Purchase of Investments
-15.95MCNYFY2025 · Dec 31, 2025Sale of Investments
17.13MCNYFY2025 · Dec 31, 2025Other Investing Activity
46.41KCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-125.41MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
1.00BCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-921.24MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-31.38MCNYFY2025 · Dec 31, 2025Other Financing Charges
257.63MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
308.21MCNYFY2025 · Dec 31, 2025Shares Outstanding
816.90MSharesUpdated Aug 19, 2026Float Shares
792.42MSharesUpdated Aug 19, 2026% Held by Insiders
61.29%vs all stocks
% Held by Institutions
0.64%vs all stocks
Total Cash (MRQ)
142.52MCNY21.17M · vs all stocks (USD)
Total Cash per Share (MRQ)
0.1740CNYUpdated Aug 19, 2026Total Debt (MRQ)
927.24MCNY137.71M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.4276xvs Biotechnology peers
Current Ratio (MRQ)
0.9360xvs Biotechnology peers
Book Value per Share (MRQ)
1.57CNYUpdated Aug 19, 2026Total Assets
4.30BCNY639.27M · vs all stocks (USD)
Total Current Assets
1.43BCNYFY2025 · Dec 31, 2025Total Liabilities
2.13BCNYFY2025 · Dec 31, 2025Total Non-current Assets
2.88BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
597.48MCNYFY2025 · Dec 31, 2025Total Current Liabilities
1.53BCNYFY2025 · Dec 31, 2025Cash
101.11MCNYFY2025 · Dec 31, 2025Cash Equivalents
20.72MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
121.83MCNYFY2025 · Dec 31, 2025Accounts Receivable
89.75MCNYFY2025 · Dec 31, 2025Inventory
1.14BCNYFY2025 · Dec 31, 2025Accounts Payable
220.40MCNYFY2025 · Dec 31, 2025Short-term Debt
654.81MCNYFY2025 · Dec 31, 2025Other Current Liabilities
5.13MCNYFY2025 · Dec 31, 2025Long-term Debt
471.94MCNYFY2025 · Dec 31, 2025Other Non-current Liabilities
2.54MCNYFY2025 · Dec 31, 2025Common Stock (Book)
816.90MCNYFY2025 · Dec 31, 2025Retained Earnings
-291.21MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
2.18BCNY323.18M · vs all stocks (USD)
52-Week Low
4.06CNYUpdated Aug 19, 202652-Week High
8.63CNYUpdated Aug 19, 202652-Week Change
-23.10%vs all stocks
Beta
0.0870xvs all stocks
50-Day MA
4.66CNYUpdated Aug 19, 2026200-Day MA
5.80CNYUpdated Aug 19, 2026Avg 10-Day Volume
7.73MSharesUpdated Aug 19, 2026Avg 30-Day Volume
9.49MSharesUpdated Aug 19, 2026Diluted EPS (TTM)
-0.1200CNYUpdated Aug 19, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Current ratio is 0.94×, lower than 95% of its Biotechnology peers (median 5.64×)Significant
Current ratio: 0.94Industry median: 5.64Industry P5: 1.06Peers compared: 261
Financial Health
Altman Z-Score 1.1: grey zoneSignificant
Altman Z-Score: 1.10
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Companies that share the same coordination system — how they create, deliver, or capture value.
BrainsWay Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Nuvectis Pharma Inc.
Tier 1ProductionApproval-Gated PipelineRule
Cytek Biosciences, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Seers Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai Xiao Feng Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Clarity Pharmaceuticals Ltd
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Zhejiang Starry Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
FDC Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Ningbo David Medical Device Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Achieve Life Sciences Inc.
Tier 1ProductionApproval-Gated PipelineRule